Cost-effectiveness of a pediatric dengue vaccine.
To ascertain the economic feasibility of a pediatric tetravalent dengue vaccine, we developed and calibrated a cost-effectiveness model of vaccinating children at 15 months in Southeast (SE) Asia using a societal perspective. We assumed that full immunization would require two doses at prices of US$ 0.50 and US$ 10 per dose in the public and private sectors, respectively. The gross cost per 1000 population (of all ages) of the vaccination program would be US$ 154. Due to projected savings in dengue treatment, the net cost per capita would be only US$ 17 (89% below the gross cost). The cost per disability adjusted life year (DALY) saved by a pediatric vaccine would be US$ 50, making the potential vaccine highly cost-effective. Eventually, vaccination may be able to replace environmental control as a strategy for dengue prevention and be cost saving.
Shepard
Donald S
DS
Schneider Institute for Health Policy, Heller School, Room G19, Mail Stop 035, Brandeis University, Waltham, MA 02454-9110, USA. shepard@brandeis.edu
Suaya
Jose A
JA
Halstead
Scott B
SB
Nathan
Michael B
MB
Gubler
Duane J
DJ
Mahoney
Richard T
RT
Wang
Daniel N C
DN
Meltzer
Martin I
MI
D001210:Asia, Southeastern / Q000453:epidemiology; D002648:Child; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003715:Dengue / Q000191:economics* / Q000276:immunology / Q000517:prevention & control*; D003716:Dengue Virus / Q000276:immunology*; D006801:Humans; D032541:Mass Vaccination / Q000191:economics; D019057:Quality-Adjusted Life Years; D014765:Viral Vaccines / Q000191:economics* / Q000276:immunology*
D014765:Viral Vaccines